» Articles » PMID: 17322888

FcgammaRIIb Controls Bone Marrow Plasma Cell Persistence and Apoptosis

Overview
Journal Nat Immunol
Date 2007 Feb 27
PMID 17322888
Citations 144
Authors
Affiliations
Soon will be listed here.
Abstract

The survival of long-lived plasma cells, which produce most serum immunoglobulin, is central to humoral immunity. We found here that the inhibitory Fc receptor FcgammaRIIb was expressed on plasma cells and controlled their persistence in the bone marrow. Crosslinking FcgammaRIIb induced apoptosis of plasma cells, which we propose contributes to the control of their homeostasis and suggests a method for therapeutic deletion. Plasma cells from mice prone to systemic lupus erythematosus did not express FcgammaRIIb and were protected from apoptosis. Human plasmablasts expressed FcgammaRIIb and were killed by crosslinking, as were FcgammaRIIb-expressing myeloma cells. Our results suggest that FcgammaRIIb controls bone marrow plasma cell persistence and that defects in it may contribute to autoantibody production.

Citing Articles

Signaling Activation and Modulation in Extrafollicular B Cell Responses.

Staniek J, Rizzi M Immunol Rev. 2025; 330(1):e70004.

PMID: 39917832 PMC: 11803499. DOI: 10.1111/imr.70004.


Booster COVID-19 mRNA vaccination ameliorates impaired B-cell but not T-cell responses in older adults.

Kometani K, Yorimitsu T, Jo N, Yamaguchi E, Kikuchi O, Fukahori M Front Immunol. 2024; 15:1455334.

PMID: 39717779 PMC: 11663736. DOI: 10.3389/fimmu.2024.1455334.


Fc-FcγR interactions during infections: From neutralizing antibodies to antibody-dependent enhancement.

Edgar J, Bournazos S Immunol Rev. 2024; 328(1):221-242.

PMID: 39268652 PMC: 11659939. DOI: 10.1111/imr.13393.


Antibody modulation of B cell responses-Incorporating positive and negative feedback.

Cyster J, Wilson P Immunity. 2024; 57(7):1466-1481.

PMID: 38986442 PMC: 11257158. DOI: 10.1016/j.immuni.2024.06.009.


Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors.

Jelinek T, Zihala D, Sevcikova T, Anilkumar Sithara A, Kapustova V, Sahinbegovic H Leukemia. 2024; 38(6):1323-1333.

PMID: 38493239 PMC: 11147761. DOI: 10.1038/s41375-024-02206-w.